A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
Radio-recurrent prostate cancer is typically detected by a rising PSA and may reflect local or distant disease. PET radiotracers targeting PSMA such as 18F-DCFPyL have shown promise in restaging men with recurrent disease post-prostatectomy but are less well characterized in the setting of radio-recurrent disease. A prospective, multi-institutional study was conducted to evaluate the impact of 18F-DCFPyL PET/CT when added to diagnostic imaging (DI; CT abdomen and pelvis, bone scan, mpMRI pelvis) for men with radio-recurrent prostate cancer. All men were imaged with DI and subsequently underwent 18F-DCFPyL PET/CT with local and central reads. Tie break reads were performed as required. Management questionnaires were completed after DI and again after 18F-DCFPyL PET/CT. Discordance in patterns of disease detected with 18F-DCFPyL PET/CT versus DI and changes in management were characterized. Seventy-nine men completed the study. Most men had T1 disease (62%) and Gleason score <7 (95%). Median PSA at diagnosis was 7.4ng/ml and at relapse was 4.8ng/ml. DI detected isolated intra-prostatic recurrence in 38/79 men (48%), regional nodal recurrence in 9/79 (11%), distant disease in 12/79 (15%), and no disease in 26/79 (33%). 18F-DCFPyL PET/CT detected isolated intra-prostatic recurrence in 38/79 men (48%), regional nodal recurrence in 21/79 (27%), distant disease in 24/79 (30%), and no disease in 10/79 (13%). DI identified 8/79 (10%) patients to have oligometastatic disease, compared to 21/79 (27%) with 18F-DCFPyL PET/CT. 18F-DCFPyL PET/CT changed proposed management in 34/79 (43%) patients. 18F-DCFPyL PET/CT identified extra-prostatic disease in twice as many men with radio-recurrent prostate cancer compared with DI and detected a site of recurrence in 87% of men compared to 67% with DI. Further, 18F-DCFPyL PET/CT identified potentially actionable disease (prostate only-recurrence or oligometastatic disease) in 75% of men and changed proposed management in 43% of men.